Does the deprescription of chondroprotectors in patients with osteoarthritis lead to an increase in the consumption of analgesics? Observational retrospective study
DOI:
https://doi.org/10.60103/phc.v24i1.665Keywords:
Osteoarthritis; SYSADOA; chondroitin sulfate; glucosamine sulfate; analgesics; deprescriptionAbstract
Objective: The objective of this study is to assess if the deprescription of medications that are considered low intrinsic value medications such as the chondroprotectors or SYSADOA entails a symptomatic worsening of the arthrosis and consequently an increase of the consumption of analgesics.
Material and Methods: Following the usual clinical practise, the SYSADOA treatment was withdrawn to the patients from a Primary Health Care Centre (assigned population: 34,382 inhabitants, 17% up to 65 years old) according to the published scientific proof and the recommendation of the health administration consisting of reducing the treatments with low intrinsic value medications. Differences in consumption of analgesics and AINEs between a previous period before the withdrawn and the same period post-withdrawn were studied through an observational post-intervention study.
Results: 354 patients were analysed (68,4% women, average age 66,2 years). There were not found significant differences from a statistical point of view in the total consumption of analgesia in the 6 months period post-withdrawn (average of 3,97 packagings) compared to the previous period of 6 months (average of 4,04 packagings). When stratifying by ATC code, age and gender, there were only found differences in the consumption of other analgesics and antipyretics taking into account the sex.
Conclusion: It is concluded that considering together with the patient the deprescription of SYSADOA according to doctor’s criteria is safe and does not involve an increase of analgesics consumption (other analgesics, antipyretics, AINEs, major and minor opiods) suggesting that it does not suppose a worsening of the arthrosis disease. Besides, the deprescription of SYSADOA may contribute to reduce polymedication without disrupting the clinical situation and avoid possible risks of adverse effects or potential interactions.
Downloads
References
Do Pazo Fernando. Los SYSADOA en la osteoartrosis: de la evidencia a la creencia. El comprimido (internet) 2019 [citado Abril 2019]. Disponible en: https://www.elcomprimido.com/es/boletines-el-comprimido/112-boletin-elcomprimido-n-23
Lawrence JS, Bremner JM, Bier F. Osteo-arthrosis. Prevalence in the population and relationship between symptoms and x-ray changes. Ann Rheum Dis. 1966;25(1):1-24. doi:10.1136/ard.25.1.1
Enquesta i examen de salut de Catalunya 2006. Departament de Salut. [Accessed March 15, 2019].Disponible en: http://www.academia.cat/files/204-6181-FITXER/ModeldatencioaldolorcronicaCatalunya
Leticia Alle Deveza. Overview of the management of osteoarthritis En: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. [Accedido el 16 de enero de 2022].
Giacovelli G RL. Clinical efficacy of glucosamine sulfate in osteoarthritis of the spine (Abstract). Rev Esp Reum. 1993;20:(Suppl 1):96.
Overview | Osteoarthritis: care and management | Guidance | NICE. Published online 2014. [Accedido el 16 de enero de 2022] Disponible en: https://www.nice.org.uk/guidance/cg177
Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64(4):465-474. doi:10.1002/acr.21596
Saila O, De Salud D. INFORMES, ESTUDIOS E INVESTIGACIÓN: Sysadoas. Condroprotectores en el tratamiento de la artrosis. Informes de Evaluación de Tecnologías Sanitarias. Osteba. Published online 2014. [Accedido 13 de febrero 2021]. Disponible en: https://www.euskadi.eus/contenidos/informacion/biblioteca_central/es_9528/scp/214787.pdf
Singh JA, Noorbaloochi S, Macdonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015;2017(6). doi:10.1002/14651858.CD005614.pub2
Sempere M, Roth P, Gonzálvez JL. Condroprotectores en la artrosis (AMF 2013) La pregunta clínica. [Accedido 13 de febrero 2021]. Disponible en: https://amfsemfyc.com/web/article_ver.php?id=1592
Surgeons. AA of O. Management of Osteoarthritis of the Hip.; 2017. [Accedido 19 de abril 2017]. Disponible en: www.orthoguidelines.org
Roman-Blas JA, Castañeda S, Sánchez-Pernaute O, et al. Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Arthritis Rheumatol. 2017;69(1):77-85. doi:10.1002/art.39819
Fernández-Liz E, López-Pareja N, Rifà-Ros A, Maudos-Pérez M. La desprescripción de fármacos sintomáticos de acción lenta para el tratamiento de la artrosis. Aten Primaria. 2014;46(9):522-523. doi:10.1016/j.aprim.2014.03.006
Pablo Méndez Valera, Inmaculada Saurí Ferrer RUT y JLTM. Adecuación de la utilización de los fármacos SYSADOAS mediante un algoritmo de decisión terapéutica para el tratamiento de la artrosis (abstract). Congr Nac SEFAP. Published online 2014:Poster no L1-22. [Accedido 13 de febrero 2021]. Disponible en: https://www.sefap.org/2019/10/23/adecuacion-farmacoterapeutica-recomendaciones/
Tonelli SM, Rakel BA, Cooper NA, et al. Women with knee osteoarthritis have more pain and poorer function than men, but similar physical activity prior to total knee replacement. Biol Sex Differ. 2011 Nov 10;2:12. doi: 10.1186/2042-6410-2-12.
Ju-Ryoung Kim, Hyun Ah Kim. Molecular Mechanisms of Sex-Related Differences in Arthritis and Associated Pain. Int J Mol Sci. 2020 Oct 26;21(21):7938. doi: 10.3390/ijms21217938.
Informe SED-POP: Siete de cada diez personas con dolor crónico presentan ansiedad o depresión · Sociedad Española del Dolor. [Accedido 14 de diciembre 2018]. Disponible en: https://www.sedolor.es/informe-sed-pop-siete-de-cada-diez-personas-con-dolor-cronico-presentan-ansiedad-o-depresion/
Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis. N Engl J Med. 2006;354(8):795-808. doi:10.1056/nejmoa052771
Fransen M, Agaliotis M, Nairn L, et al. Glucosamine and chondroitin for knee osteoarthritis: A double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015;74(5):851-858. doi:10.1136/annrheumdis-2013-203954
Dougados M, Nguyen M, Berdah L, Maziéres B, Vignon E, Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum. 2001;44(11):2539-2547. doi:10.1002/1529-0131(200111)44:11<2539::AID-ART434>3.0.CO;2-T
Rozendaal RM, Koes BW, Van Osch GJVM, et al. Effect of glucosamine sulfate on hip osteoarthritis: A randomized trial. Ann Intern Med. 2008;148(4):268-277. doi:10.7326/0003-4819-148-4-200802190-00005
Wandel S, Jüni P, Tendal B, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: Network meta-analysis. BMJ. 2010;341(7775):711. doi:10.1136/bmj.c4675
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Anna Barraquer Comes, Inés Monge Escartín , Asunción Álvarez Carrera, Marta de Antonio Cusco, Óscar Peral Alonso
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
La revista Pharmaceutical Care España se publica bajo una licencia «Creative Commons, Reconocimiento, No Comercial y Compartir Igual 4.0 Internacional» (CC BY-NC-SA 4.0)», que permite a otros compartir el trabajo con un reconocimiento de la autoría del trabajo y la publicación inicial en esta revista (con excepción de los usos comerciales).
Los autores que publican en esta revista están de acuerdo con los siguientes términos:a) Los autores conservan los derechos de autor (derechos morales) y garantizan a la revista el derecho de ser el primer soporte documental publicado del trabajo.
b) Se permite y anima a los autores a difundir la versión del trabajo revisado por pares y aceptada para su publicación (por ejemplo, en repositorios institucionales o temáticos), recomendando hacerlo con la versión final del editor “pdf”, “html” o “xml”).
